65,437 trials
Safety
Primary: Number of Participants With at Least 1 Adverse Event (AE) — 68; 58; 17; 15 participants
Primary Osteoarthritis of Knee Nos
Primary: Perioperative Blood Loss — 546.9; 475.0; 430.2; 329.2 ml — p=<0.05
Atrial Fibrillation
Primary: Real-time Documentation of Pulmonary Vein Disconnection — 125 number of PVs disconnected in realtime
Healthy
Primary: Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxytryptamine (5-HT) in Plasma — 4183024; 3854399; 4224058; 3912292 pg*hr/mL
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Quadrivalent Influenza Vaccine or Fluzone® Trivalent…
Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer
Primary: 2-Month Cumulative Incidence of VTE — 5.6; 27.2; 7.2 percent probability — p=0.06
Tuberculosis
Primary: To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants. — 95.9; 83.7 percentage of all subjects vaccinated
Adult Diffuse Large Cell Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma · Stage IV Adult Diffuse Large Cell Lymphoma
Primary: Objective Tumor Response — 0 participants
Dry Eye Syndromes
Primary: Change in Fluorescein Corneal Staining (FCS) Score From Baseline — -3.7; -2.9 units on a scale — p=<0.05
Chemotherapy-Induced Nausea and Vomiting · Postoperative Nausea and Vomiting
Primary: Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V — 29215; 24961; 31724 ng*hr/mL
HIV Infections
Primary: Immunoglobulin G (IgG) Levels — 5.12; 5.17; 1.80; 1.83 Micrograms/ml
Diabetes Mellitus · Obesity
Primary: Change From Baseline in Body Weight at 48 Weeks — -9.5; -8.5 percentage of weight loss
Healthy
Primary: Incidence of Adverse Events — 5; 4; 6; 6 Participants
Anesthesia
Primary: Percent of Subjects Requiring Rescue Midazolam for Sedation — 0 percentage of participants
Asthma
Primary: Effect of MEDI-528 on Late Asthmatic Response (LAR) After Inhaled Allergen Challenge at Day 7 — 21.26; -16.21 Percent — p=0.168